Baltimore Capital Management’s Celgene Corp CELG Stock Holding History

Baltimore Capital Management’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$241K	Buy	+2,550	New	+$223K	0.39%	66
2018 Q2	–	Sell	-5,620	Closed	-$501K	–	77
2018 Q1	$501K	Buy	5,620 +1,845	+49%	+$177K	0.75%	37
2017 Q4	$394K	Buy	3,775 +1,575	+72%	+$178K	0.55%	50
2017 Q3	$321K	Sell	2,200 -100	-4%	-$13.6K	0.45%	55
2017 Q2	$299K	Buy	2,300 +350	+18%	+$42.9K	0.43%	56
2017 Q1	$243K	Buy	+1,950	New	+$233K	0.32%	61

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Baltimore Capital Management's CELG Position: Q1 2019 in Review

Baltimore Capital Management opened a new position in Celgene Corp (CELG) in Q1 2019: 2,550 shares worth $241K. The stake represents 0.39% of the portfolio and ranks #66 among its holdings. This is a return to the name: Baltimore Capital Management previously reported a position in CELG as recently as Q1 2018.

Baltimore Capital Management first reported a position in CELG in Q1 2017 and has held it in 6 quarters since. The position peaked at $501K in Q1 2018. 1,389 funds tracked by Wall St. Rank hold CELG as of Q1 2019.

Baltimore Capital Management held 2,550 shares of Celgene Corp worth $241K as of Q1 2019.
Celgene Corp was a new Baltimore Capital Management position in Q1 2019.
Celgene Corp made up 0.39% of Baltimore Capital Management's portfolio in Q1 2019, its #66 holding.
Baltimore Capital Management first reported a position in Celgene Corp in Q1 2017 and has held it in 6 quarters since.
Baltimore Capital Management's Celgene Corp position peaked at $501K in Q1 2018.
1,389 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2019.

Based on Baltimore Capital Management's 13F filing for Q1 2019, filed 14 May 2019.